Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial (EASE‐1)

AIMS: To investigate the pharmacodynamics, efficacy and safety of empagliflozin as adjunct to insulin in patients with type 1 diabetes. METHODS: A total of 75 patients with glycated haemoglobin (HbA1c) concentrations of ≥7.5 to ≤10.5% (≥58 to ≤91 mmol/mol) were randomized to receive once‐daily empag...

Descripción completa

Detalles Bibliográficos
Autores principales: Pieber, T. R., Famulla, S., Eilbracht, J., Cescutti, J., Soleymanlou, N., Johansen, O. E., Woerle, H. J., Broedl, U. C., Kaspers, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745028/
https://www.ncbi.nlm.nih.gov/pubmed/26080652
http://dx.doi.org/10.1111/dom.12494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745028/
https://www.ncbi.nlm.nih.gov/pubmed/26080652
http://dx.doi.org/10.1111/dom.12494

Ejemplares similares